Plasma collection

OTHER4 trials

Sponsors

Northwestern University, University of Michigan Rogel Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Assistance Publique Hopitaux De Marseille

Conditions

GlioblastomaHepatocellular CarcinomaLeiomyosarcomaMetastatic Clear Cell Renal Carcinoma

Unknown Phase

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

TerminatedNCT03203837

Northwestern UniversityHepatocellular Carcinoma

Start: 2017-07-05End: 2020-01-06Updated: 2020-09-09

Metastatic Leiomyosarcoma Biomarker Protocol

RecruitingNCT05653388

University of Michigan Rogel Cancer CenterLeiomyosarcoma

Start: 2022-12-22End: 2026-12-01Target: 200Updated: 2026-06-24

Multiomics Approach in Metastatic Clear Renal Cell Carcnoma

Active, not recruitingNCT05782400

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoMetastatic Clear Cell Renal Carcinoma

Start: 2023-02-28End: 2027-09-30Target: 100Updated: 2025-09-03

Predictive Value of Soluble CD146 in Glioblastoma Patients

RecruitingNCT06001281

Assistance Publique Hopitaux De MarseilleGlioblastoma

Start: 2024-01-30End: 2026-12-31Target: 55Updated: 2024-02-02

Related Papers

Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31).

Journal of Clinical Oncology2024-01-291 citations